Karyopharm stock soars on se­linex­or's pos­i­tive PhI­Ib up­date, plans for an NDA

Af­ter spook­ing some in­vestors who were wait­ing all day for a promised tri­al up­date — and send­ing its stock down 14% on the per­ceived de­lay — Karyopharm Ther­a­peu­tics $KP­TI fi­nal­ly rolled out new da­ta on its lead can­cer drug se­linex­or af­ter mar­ket close Mon­day. In­vestors ap­pear to be hap­py with the news af­ter all, boost­ing the stock price 26% in af­ter-hours trad­ing.

The drug was be­ing test­ed among mul­ti­ple myelo­ma pa­tients who had proved re­sis­tant to a long slate of drugs, an in­di­ca­tion of just how crowd­ed MM has grown in re­cent years. In this da­ta up­date — the sec­ond from Karyopharm’s Phase IIb tri­al called STORM — se­linex­or achieved a 25.4% over­all re­sponse rate, which in­clud­ed two com­plete re­spons­es and 29 par­tial or very good par­tial re­spons­es in pa­tients.  The me­di­an du­ra­tion of re­sponse, a key sec­ondary ob­jec­tive, was 4.4 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER